The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The U.S. FDA advisory panel is set to vote today on whether the benefits of Moderna's new mRNA flu vaccine outweigh its risks for older adults. This formal review follows a significant regulatory reversal where the FDA initially declined the application before allowing it to proceed, making this vote a critical hurdle for market approval.
This development occurs as Moderna seeks to diversify its revenue beyond COVID-19 products. Clinical data published in the NEJM (May 2026) indicated that the mRNA-1010 vaccine was 26.6% more effective than standard-dose comparators. However, Jefferies analysts noted that the regulator might require post-marketing studies for the 65+ demographic, while the stock faces a cautious consensus with a median price target of $45.00, implying potential downside from current levels per market data.
Sign in to access this content
Sign InModerna (MRNA) closed at $61.80 (close June 17, 2026), having traded in a range between $54.51 and $62.30. Investors are focused on today's panel outcome as a primary catalyst, ahead of a final FDA decision expected by August. Additionally, market sentiment may be influenced by the Michigan Consumer Sentiment index due on June 12, according to the economic calendar.